A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

NCT02727699 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Dementia, Alzheimer Type

Interventions

DRUG: Xanamem™
DRUG: Placebo (for Xanamem™)

Sponsor

Actinogen Medical

Collaborators

[object Object]